AC Immune Announces Upcoming Presentations at the 16^th CTAD Conference

Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the 16^th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place in Boston, USA, on October 24-27, 2023.

Abeta targeted immunotherapy
Anti-Abeta liposomal vaccine, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies
Poster number: LP130
Date: October 25-27 | Available on the digital platform of CTAD at all times
Presenter: Marie Kosco-Vilbois (AC Immune)

Biomarker and clinical correlations for amyloid targeting monoclonal antibody (mAb) treatment responses
Poster number: P147
Date: October 25-27 | Available on the digital platform of CTAD at all times
Presenter: Jonathan Wagg (AC Immune)

Tau targeted immunotherapy
ACI-35.030 anti-phospho-Tau active immunotherapy for the treatment of early Alzheimer’s Disease (AD): Update from the Phase 1b/2a study data and perspectives.
Poster number: LP031
Date: October 25-27 | Available on the digital platform of CTAD at all times
Presenter: Olivier Sol, M.D. (AC Immune)

About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen^® and Morphomer^®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.

SupraAntigen^® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer^® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward- looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment

• 20231017_ACIU_CTAD Curtain Raiser